Efficacy News and Research

RSS

FDA approves Omnaris, new hay fever drug

The U.S. Food and Drug Administration (FDA) has announced the approval of Omnaris (ciclesonide) nasal spray, a new drug for the treatment of nasal symptoms associated with seasonal and perennial allergic rhinitis, commonly known as hay fever, in adults and children 12 years of age and older.

23 Oct 2006

Targeted tumor therapy has paramount consequences for future expansion of nuclear medicine

Targeted tumor therapy lobs toxic payloads directly into tumors to destroy cancer cells while leaving normal cells unharmed.

20 Oct 2006

FDA advisory panel recommends adding warning label to Tamoxifen

An FDA advisory panel on Wednesday recommended that a warning label be added to tamoxifen, an agency-approved drug for treating and preventing breast cancer, the AP/Seattle Post-Intelligencer reports (Bridges, AP/Seattle Post-Intelligencer, 10/18).

19 Oct 2006

NicOx announces EMEA approval of Naproxcinod study plan

NicOx S.A today announced that it has received scientific advice on its proposed phase 3 clinical plan for naproxcinod (HCT 3012) from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA).

17 Oct 2006

National Eye Institute to finance two-year study comparing effectiveness of treatments for macular degeneration

The National Eye Institute on Thursday said it will finance a two-year study comparing the effectiveness of Genentech's eye treatment Lucentis and cancer drug Avastin for treating wet age-related macular degeneration, the New York Times reports.

8 Oct 2006

Ho Chi Minh City to expand access to HIV/AIDS treatment for pregnant women

Ho Chi Minh City, Vietnam, will expand access to no-cost HIV/AIDS treatment for pregnant women to prevent mother-to-child transmission of HIV, city health officials said Saturday, Vietnam News Service/Viet Nam News reports (Vietnam News Service/Viet Nam News).

5 Oct 2006

Temperature-sensitive nanoparticle boosts drug antitumor activity

Using temperature-sensitive, lipid- and polymer-based nanoparticles with a polymer coating, researchers in Korea have created an anticancer drug delivery vehicle that may provide a significant boost to the therapeutic efficacy of anticancer agents, particularly when used in conjunction with hyperthermia.

2 Oct 2006

HPV vaccine Gardasil approved for sale in EU

The European Commission on Friday approved Merck's human papillomavirus vaccine Gardasil for sale and marketing in the European Union, London's Guardian reports (Batty, Guardian, 9/22).

26 Sep 2006

Use of unapproved drugs in the U.S.

USA Today on Monday looked at the use of unapproved drugs in the U.S., including some that are used to treat menopause symptoms (Rubin, USA Today, 9/18).

20 Sep 2006

1.6 million American adults use some form of complementary medicine to treat insomnia

A recent analysis of national survey data reveals that over 1.6 million American adults use some form of complementary and alternative medicine (CAM) to treat insomnia or trouble sleeping according to scientists at the National Center for Complementary and Alternative Medicine (NCCAM), part of the National Institutes of Health.

19 Sep 2006

FDA approves Noxafil (posaconazole) to prevent invasive fungal infections

The U.S. Food and Drug Administration has approved Noxafil (posaconazole) to prevent fungal infections caused by certain molds and yeast-like fungus called Aspergillus and Candida.

19 Sep 2006

AIDS Vaccines: The Next Frontiers

The AIDS Vaccine Advocacy Coalition on Thursday released its annual report, titled "AIDS Vaccines: The Next Frontiers," which says that without sufficient future planning, AIDS vaccine research could be slowed.

18 Sep 2006

Uroplasty receives FDA approvable letter for treatment of female stress urinary incontinence

Uroplasty, Inc. has announced that it has received an approvable letter from the U.S. Food and Drug Administration (FDA) relating to its pre-market approval (PMA) application for Macroplastique Implants for the treatment of female stress urinary incontinence (SUI).

14 Sep 2006

Studies on effects of drugs on children often not published

According to a new study by researchers at Duke University Medical Center, many of the drugs that are prescribed for children may not in fact be either safe or effective for pediatric use and could require different doses than is recommended.

13 Sep 2006

Study compares delivery methods of schizophrenia medicines

More than half of schizophrenia patients don't take their medication as directed and a new study will determine whether biweekly physician visits and injectable drugs can change that.

12 Sep 2006

Colchicine delays development of hepatocellular carcinoma in patients with hepatitis virus-related liver cirrhosis

Colchicine, an anti-inflammatory drug most often used to treat gout, prevented liver cancer in patients with hepatitis virus-related end-stage liver disease, according to a new study.

11 Sep 2006

First drug-eluting stent approved in Europe for most severe form of arterial disease in the leg

Cordis Endovascular, a division of Cordis Corporation, announced today that the Cypher Select Sirolimus-eluting stent received CE (Communite European) Mark in Europe for use in the treatment of severe claudication and critical limb ischemia (CLI) of infrapopliteal lesions, which is the most severe form of arterial disease in the leg.

6 Sep 2006

Licensing arrangement reached for antiepileptic drug developed at Hebrew University

A worldwide licensing arrangement for development, production and marketing of an antiepileptic drug created at the Hebrew University of Jerusalem has been signed by Shire Pharmaceuticals with Yissum, the Hebrew University's technology transfer company.

5 Sep 2006

Endovascular repair of thoracic and abdominal aortic diseases as an alternative to open surgery in patients at high surgical risk

World Congress of Cardiology Report - Acute aortic syndromes, such as large thoracic and abdominal aortic aneurysms with impending rupture, complicated acute type B dissections, traumatic rupture of thoracic aorta, still represent life-threatening conditions.

5 Sep 2006

Aspirin resistance: Fact or fable?

Coronary heart disease is the single leading cause of death in the Western world. Aspirin is a fundamental part of the prevention and treatment of coronary heart disease and is used by millions of patients worldwide.

5 Sep 2006

Efficacy News and Research

FDA approves Omnaris, new hay fever drug

Targeted tumor therapy has paramount consequences for future expansion of nuclear medicine

FDA advisory panel recommends adding warning label to Tamoxifen

NicOx announces EMEA approval of Naproxcinod study plan

National Eye Institute to finance two-year study comparing effectiveness of treatments for macular degeneration

Ho Chi Minh City to expand access to HIV/AIDS treatment for pregnant women

Temperature-sensitive nanoparticle boosts drug antitumor activity

HPV vaccine Gardasil approved for sale in EU

Use of unapproved drugs in the U.S.

1.6 million American adults use some form of complementary medicine to treat insomnia

FDA approves Noxafil (posaconazole) to prevent invasive fungal infections

AIDS Vaccines: The Next Frontiers

Uroplasty receives FDA approvable letter for treatment of female stress urinary incontinence

Studies on effects of drugs on children often not published

Study compares delivery methods of schizophrenia medicines

Colchicine delays development of hepatocellular carcinoma in patients with hepatitis virus-related liver cirrhosis

First drug-eluting stent approved in Europe for most severe form of arterial disease in the leg

Licensing arrangement reached for antiepileptic drug developed at Hebrew University

Endovascular repair of thoracic and abdominal aortic diseases as an alternative to open surgery in patients at high surgical risk

Aspirin resistance: Fact or fable?

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News